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Introduction: Mitochondrial dysfunction and oxidative stress are critical factors in the pathogenesis of age-dependent
neurodegenerative diseases. PGC-1α, a master regulator of mitochondrial biogenesis and cellular antioxidant defense,
has emerged as a possible therapeutic target for Parkinson’s disease, with important roles in the function and survival
of dopaminergic neurons in the substantia nigra. The objective of this study is to determine if the loss of PGC-1α
activity contributes to α-synuclein-induced degeneration.
Results: We explore the vulnerability of PGC-1α null mice to the accumulation of human α-synuclein in nigral neurons,
and assess the neuroprotective effect of AAV-mediated PGC-1α expression in this experimental model. Using neuronal
cultures derived from these mice, mitochondrial respiration and production of reactive oxygen species are assessed in
conditions of human α-synuclein overexpression. We find ultrastructural evidence for abnormal mitochondria and
fragmented endoplasmic reticulum in the nigral dopaminergic neurons of PGC-1α null mice. Furthermore, PGC-1α null
nigral neurons are more prone to degenerate following overexpression of human α-synuclein, an effect more apparent
in male mice. PGC-1α overexpression restores mitochondrial morphology, oxidative stress detoxification and basal
respiration, which is consistent with the observed neuroprotection against α-synuclein toxicity in male PGC-1α null mice.
Conclusions: Altogether, our results highlight an important role for PGC-1α in controlling the mitochondrial function of
nigral neurons accumulating α-synuclein, which may be critical for gender-dependent vulnerability to Parkinson’s disease.
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In Parkinson’s disease (PD), the age-dependent loss of dopa-
minergic neurons in the substantia nigra pars compacta
(SNpc) has been linked to mitochondrial dysfunction.
Alterations of the electron transport chain (ETC) activity
can be caused by environmental factors, such as accidental
exposure to 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine
(MPTP) [1,2]. Similarly, a parkinsonian syndrome charac-
terized by selective nigral degeneration can be induced in
rodents following chronic mitochondrial intoxication with
rotenone, which impairs mitochondrial complex I activ-
ity [3]. The aging process may also cause the accumulation
of genetic defects in mitochondrial DNA, thereby contrib-
uting to neurodegeneration in PD [4,5].* Correspondence: bernard.schneider@epfl.ch
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gained further support when PD-associated genetic fac-
tors, such as α-synuclein (aSyn), LRRK2, parkin, PINK1
and DJ-1, were shown to be involved in the function and
turnover of mitochondria. Notably, the ubiquitin ligase
parkin and the mitochondrial kinase PINK1, which are
linked to autosomal recessive juvenile PD [6,7], control
the autophagic clearance of defective mitochondria [8,9].
DJ-1 maintains proper mitochondrial function in re-
sponse to oxidative stress [10].
Multiplications or point mutations in the gene encoding
aSyn, an abundant presynaptic protein, are associated with
autosomal dominant familial PD. Accumulation or muta-
tions of the aSyn protein increase its propensity to adopt a
β-sheet conformation, thereby producing oligomers and
fibrils that accumulate in Lewy bodies. Alpha-synuclein
interacts with the mitochondrial outer membrane, in-
ducing mitochondrial fragmentation [11-13]. Transgenic
mice expressing human aSyn show pathogenic impairmentshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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aSyn-null mice often display increased resistance to
MPTP [16,17].
Factors modulating mitochondrial activity have emerged
as novel therapeutic targets in PD. Peroxisome proliferator-
activated receptor gamma coactivator-1α (PGC-1α) is a
master transcriptional regulator of cell metabolism,
controlling the expression of nuclear genes implicated
in mitochondrial biogenesis and resistance to oxidative
stress [18]. In neuronal cultures from the ventral midbrain,
PGC-1α increases mitochondrial mass and basal res-
piration [19], and transgenic mice overexpressing PGC-1α
in dopaminergic neurons are more resistant to MPTP [20].
A meta-analysis of gene expression changes in the SN of
human PD patients has revealed underexpression of
PGC-1α target genes implicated in mitochondrial func-
tion, consistent with a loss of PGC-1α activity that may
play a key role in disease pathogenesis [21]. Furthermore,
reduced PGC-1α activity has recently been shown to
enhance aSyn oligomerization, which in turn downre-
gulates PGC-1α expression [22].
Unexpectedly, chronic supraphysiologic expression of
PGC-1α selectively impairs dopaminergic function in adult
rats and mice [19,23]. Nevertheless, it is also important to
explore if decreased PGC-1α activity, which presumably
occurs in the aged, parkinsonian brain [24], is linked to
neuronal loss in sporadic PD. Although PGC-1α null mice
do not spontaneously develop a parkinsonian syndrome,
they display higher sensitivity to oxidative stress and exci-
totoxic injuries [18]. Here, we hypothesized that the loss of
PGC-1α activity may increase the vulnerability to aSyn via
perturbations of the mitochondrial activity and reduced de-
toxification of reactive oxygen species (ROS). To address
this possibility, we used null mice with disrupted expres-
sion of full-length PGC-1α (PGC1α-KO) [25]. We report
that nigral dopaminergic neurons in PGC1α-KO mice
show abnormal mitochondria and fragmented endoplasmic
reticulum (ER). Furthermore, these neurons are more
prone to degenerate following overexpression of human
aSyn. This effect is more apparent in male PGC1α-KO
mice and can be rescued by AAV-mediated expression
of PGC-1α. Altogether, our results highlight a gender-




Human wild-type (WT) aSyn (nucleotides 46–520,
GeneBank accession no. NM_000345) and full-length
mouse PGC-1α (nucleotides 35–2428, GeneBank accession
no. BC066868) were inserted into the pAAV-pgk-MCS
backbone, modified from the serotype 2 pAAV-cmv-MCS
(Agilent, La Jolla, CA, USA) using standard cloning
procedures. To enhance transgene expression, regulatoryelements including an optimized kozak consensus sequence
and the Woodchuck hepatitis virus Post-transcriptional
Regulatory Element (WPRE), were inserted into pAAV-
pgk-MCS, leading to our 2nd generation vector which was
used for enhanced expression of human WT aSyn [26].
The pAAV-cmv-MitoDsRed plasmid was generated by
subcloning the coding sequence for DsRed2 fused to a
mitochondrial localization signal into the pAAV-cmv-MCS
backbone.
Recombinant AAV production and titration
Recombinant pseudotyped rAAV2/6 were produced, puri-
fied and titrated as described previously [19]. A stuffer se-
quence was included in the plasmid pAAV-pgk-MCS to
generate a non-coding vector with a comparable genome
size. The measured titers were as follows: AAV-pgk-
aSynWT 1.1 × 1010 TU/ml; AAV-pgk-Kz-aSynWT-WPRE
2.1 × 1010 TU/ml; AAV-pgk-MCS (non-coding vector)
7.8 × 1010 TU/ml; AAV-pgk-PGC-1α 7.4 × 1010 TU/ml.
Except for expression of mitoDsRed, serotype 6 pseu-
dotyped particles were used in the present study. The
AAV-cmv-MitoDsRed vector was packaged into serotype
8 AAV particles as described previously [27], with a titer
of 9.4 × 1012 VG/ml. The serotype 8 was preferred in this
case to avoid retrograde transduction of neurons in the
striatum [27].
Stereotaxic unilateral injection into the SNpc of mice
Young adult (6 and 8 weeks old) C57BL/6J (Charles River
Laboratories, France) and PGC1α-KO mice were housed
in a 12 hrs light/dark cycle, with ad libitum access to food
and water, in accordance with Swiss legislation and the
European Community Council directive (86/609/EEC)
for the care and use of laboratory animals. The line of
PGC1α-KO mice was generated and first described
[25] by the Laboratory of Dr. Daniel Kelly at Sanford-
Burnham Medical Research Institute (Orlando, FL) and
backcrossed into C57BL/6J for 10 generations. For the
present study, the PGC1α-KO mice were bred at EPFL.
For stereotaxic injections, the animals were deeply anes-
thetized with a mixture of xylazine/ketamine and placed
in the stereotaxic frame (David Kopf Instruments,
Tujunga, CA, USA). 1 μl of viral preparation, was injected
in the right brain hemisphere using a 10 μl Hamilton syr-
inge with a 34-gauge blunt tip needle at a speed of 0.2 μl/
min, using an automatic pump (CMA Microdialysis,
Sweden). The total injected vector load was 1 × 107 TU
for a single vector injection, and 1.5 × 107 TU when two
vectors were co-injected. The needle was left in place for
an additional 5 min before being slowly withdrawn. The
SNpc was targeted at the following coordinates: anterio-
posterior (AP) -2.9 mm and mediolateral (ML) 1.3 mm
relative to bregma, dorsolateral (DV) -4.2 mm relative
to skull surface.
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SNpc of 10-month old mice, we used the following coor-
dinates: antero-posterior (AP) -2.9 mm and mediolateral
(ML) 1.6 mm relative to bregma, dorsolateral (DV)
-4.9 mm relative to skull surface.Primary neuronal culture from mouse cerebral cortex
The protocol used for the preparation of the primary
neuronal cultures from mouse cerebral cortex was
adapted from reference [19]. Cortices of embryonic
brains (E16.5) were dissected under a microscope and
kept in cold Hank’s buffered salt solution (HBSS) w/o
Ca2+ and Mg2+. Tissues were dissociated by gentle tritur-
ation through a Pasteur pipette. Cells were resuspended
in MEM medium supplemented with 10% heat inacti-
vated horse serum, GlutaMAX 1X and 1% Pen-Strep
and filtered (0.22 μm). The cell concentration and the
viability were determined using a classic dye exclusion
method (Trypan Blue). Neurons were seeded onto 24-well
culture plates precoated with poly-D-lysine (100 mg/ml)
and laminin (mg/ml) at a density of 1 × 105 cells per well.
Plates were maintained at 37°C in a humidified atmos-
phere of 5% CO2. Three hours after plating, medium was
removed and replaced by Neurobasal medium supple-
mented with B27 (1X), GlutaMAX (1X) and 1% Pen-Strep.
Seven-day-old cultures were used for AAV infections. For
AAV-mediated transduction, each 24-well was infected
with a viral dose of 6 × 106 TU.Measurements of oxygen consumption
Oxygen measurements were made using the XF96 Extra-
cellular Flux Analyzer (Seahorse Bioscience, Billerica, MA).
Primary cortical neurons were seeded in pre-coated XF96-
well microplates at 4.0 × 104 cells per well and cultured for
5 days in regular conditions. Neurons were then trans-
duced with AAV2/6 vectors at a total dose of 1 × 106 TU.
Seven days after infection, cells were used for analysis
of oxygen consumption. Two days before measure-
ment, 75% of the culture medium was replaced by
Neurobasal A medium (GIBCO, 005-0128DJ) supple-
mented with 2 mM glucose, 25 mM pyruvate, 100 U/ml
Penicillin-Streptomycin, 2 mM glutamax and B27. One
day before measurement the cartridge with electrodes
was subjected to automatic calibration. Basal oxygen
consumption rate (OCR) was measured four times over
30 min. Cells in separate wells were next exposed to either
oligomycin (5 μM) or CCCP (10 μM) for 35 min and res-
piration rate was measured five times. The average of the
first two measures of CCCP-induced OCR were used for
calculation of the spare respiratory capacity. Calculations
of oligomycin-resistant respiration and percentage of OCR
used for ATP production were based on the average of five
OCR measurements in oligomycin-treated cells.Immunohistological analyses and quantification of
nigrostriatal lesions
Mice were sacrificed and tissue processed as described
previously [19]. Primary antibodies used in this study
were anti-TH (Rabbit IgG, 1:1000; AB152, Chemicon
and mouse IgG for triple staining, 1:800; Sigma-Aldrich),
anti-cleaved Caspase 3 (Rabbit IgG, 1:500; Cell Signaling),
anti-aSyn (Sheep IgG, 1:400; Chemicon), anti-PGC-1α
(rabbit IgG, 1:1000; generous gift from Daniel Kelly,
Sanford-Burnham Medical Research Institute, Orlando,
FL, USA), anti-4-Hydroxynonenal (HNE) (Rabbit IgG,
1:1000; Alexis). For fluorescence labeling, we used second-
ary antibodies conjugated to Alexa Fluor-488 (1:500;
Invitrogen), Cy3 (1:1000; Jackson ImmunoResearch),
AMCA (1:100; Vector Laboratories). For bright-field
microscopy, we used biotinylated goat anti-rabbit secondary
antibody (1:200; Vector Laboratories).
To analyze mitoDsRed-labeled mitochondria in the
dorsolateral region of the striatum of 10-month old
mice, 4 weeks after injection of the AAV-mitoDsRed
vector, coronal brain sections were subjected to confocal
microscopy analysis using a Zeiss LSM700 UP2 micro-
scope with a 40x objective. Three images were arbitrarily
taken from three different brain sections of each animal,
and the density of mitochondria was measured by normal-
izing the number of discrete mitoDsRed signals to the
dopaminergic axon area, as determined by the surface of
TH immunoreactivity. Images were processed using
ImageJ, Huang and Triangle were selected as proper
algorithms to set threshold for mitochondria and axons,
respectively.
Stereological estimates of Nissl-positive and TH-positive
nigral neurons were obtained as described previously [19].
The extent of striatal dopaminergic innervation was mea-
sured by determining the optical density for TH on DAB-
immunostained brain slices regularly distributed over
the entire striatum. All immunohistochemical evalua-
tions were performed in a blinded manner.
Transmission electron microscopy
Adult 10 months-old mice were perfused via the heart
with 2.5% glutaraldehyde and 2% paraformaldehyde in
0.1 M phosphate buffer at pH 7.4. After 2 hrs the brains
were removed and vibratome sectioned coronally, at
80 μm thickness, at the level of the SN. The sections
were washed in 0.1 M cacodylate buffer, post-fixed in
1.5% potassium ferrocyanide, followed by 1% osmium
tetroxide, and then 1% uranyl acetate, for 40 min in each
solution. They were then dehydrated in a graded alcohol
series, embedded in Durcupan resin (Fluka, Switzerland)
and then mounted between two glass microscope slides
before being hardened at 60°C for 48 hrs. The region of
interest was selected using a stereomicroscope and trans-
mitted light to image the brain sections. Using a razor
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blank resin block for further trimming and sectioning.
Ultrathin sections were cut at 50 nm and collected
onto formvar coated nickel slot grids, and imaged at
80 kV in a transmission electron microscope (Tecnai
Spirit FEI), and images collected with a CCD camera at
a resolution of approximately 2 nm per pixel (FEI Eagle).
From each mouse, single thin sections of the SN and
VTA were systematically scanned, and every neuronal
cell body in which a nucleus could be seen was imaged.
In total, 79, 89 and 113 cell bodies were imaged in the SN
of WT, PGC1α-KO and PGC1α Inj conditions, respect-
ively. Then electron microscopy images were analyzed
using ImageJ software. Three mice were analyzed per
group, corresponding to a total number of 2729, 3527 and
2544 mitochondria in WT, PGC1α-KO and PGC1α Inj,
respectively. In the VTA, 51 and 95 cell bodies were
imaged in WT and PGC1α-KO mice, respectively. Three
mice were similarly analyzed per group, corresponding to
a total number of 4110 and 7265 mitochondria in WTand
PGC1α-KO mice, respectively.
RNA extraction and RT-qPCR
To determine the level of PGC-1α and PGC-1β mRNA
in the SN, age-matched WT, PGC1α-KO and AAV-
PGC-1α-injected mice were sacrificed by decapitation.
The AAV vector encoding mouse PGC-1α was injected
3 weeks before animal sacrifice (n = 3 per group). In each
mouse, the SN was rapidly dissected and transcript abun-
dance measured by reverse transcription-quantitative PCR
(RT-qPCR). Total RNA was isolated with an RNAeasy
Mini Kit (Qiagen). cDNA was prepared using a Omnis-
cript Reverse Transcription Kit. Briefly, total RNA (50 ng)
was reverse transcribed in a final volume of 20 μl with
OligodT primers at 37°C for 1 hr according to the
manufacturer’s instructions. The expression levels of
PGC-1α and PGC-1β were measured by RT-qPCR using
SybrGreen assays. The genes ACTB and B2M were used
as endogenous controls. We used Quantitect Primer
Assays (Qiagen) to quantify expression of these 4 genes.
Each assay was run in duplicate, with the Rotor-Gene Sybr
Green PCR Kit (Qiagen) on a Rotor-Gene Cycler using
the following cycling conditions: 5 min at 95°C, then 5 sec
at 95°C and 10 sec at 60°C for 40 cycles. Each replicate’s
cycle threshold (Ct) was normalized to the average Ct of
the two endogenous controls on a per sample basis. The
comparative Ct method was used to calculate relative
levels of PGC-1α and PGC-1β expression, as described
in [28].
Measurements of H2O2 concentration
Primary cortical neurons were seeded in precoated 24-well
plates at 1x105 cells per well and cultured for 7 days in
37°C/5% CO2 incubators. Neurons were co-infectedwith AAV2/6 vectors at a dose of 6 × 106 TU for each
vector. Measurements of H2O2 concentration in the
culture medium were made using Amplex Red Hydrogen
Peroxide/Peroxidase Assay Kit (Invitrogen). Fifty μl of the
standard curve samples and experimental samples were
added to individual wells of a microplate, as well as 50 μl
of the Amplex Red reagent/HRP working solution. After
30 min of incubation at room temperature, plates were
analyzed on a fluorometer (Tecan Safire2 microplate
reader) using wavelengths at 530 nm for excitation and
585 nm for emission.
Statistical analysis
Data are expressed as average ± standard error of the
mean (SEM). Statistical analysis was performed using
the Statistica software (StatSoft Inc., OK, USA). The
alpha level of significance was set at 0.05. Applied statis-
tical tests are indicated in the Figure legends.
Results
Transcriptional activity of genes related to mitochondrial
function is changed in PGC1α-KO mice
To assess how PGC-1α activity impacts on nigral dopa-
minergic neurons, we used PGC1α-KO mice obtained
by homologous recombination, with an incomplete tar-
geting of the mouse PGC-1α coding sequence [25].
Although the expression of full length PGC-1α is al-
most completely extinguished in homozygous mice,
they retain the potential to produce a truncated form
of the protein (amino acids 1–254), named NT-PGC-
1α254, and which is functionally similar to the nat-
ural splice variant NT-PGC-1α [29,30].
PGC1α-KO mice were compared to control wild-type
(WT) C57BL/6J mice, from the same genetic back-
ground. In order to perform rescue experiments and re-
store PGC-1α activity, we designed an AAV2/6 vector
for constitutive expression of PGC-1α following injec-
tion in the adult SNpc.
First, we assessed PGC-1α expression in the SNpc
(Figure 1a). RT-qPCR revealed in adult PGC1α-KO mice
a 9.7-fold reduction in the level of the PGC-1α transcript
(0.10 ± 0.04 Arbitrary Units (AU)), as compared to WT
mice (1.0 ± 0.1 AU). Of note, PCR primers were designed
to amplify a region between exon 5 and exon 6 of the
PGC-1α gene transcript, which is predicted to be non-
transcribed in PGC1α-KO mice [25]. In PGC1α-KO
mice injected with 1x107 TU of AAV2/6 vector express-
ing PGC-1α (PGC1α Inj), we measured at three weeks
after injection a 11.8-fold increase in the abundance of
the PGC-1α transcript in the SNpc (11.8 ± 1.7 AU), as
compared to endogenous level in WT mice.
Next, we sought to explore if the loss of PGC-1α activity
could modify expression of PGC-1β, a closely related














































WT PGC1α-KO PGC1α Inj 
Figure 1 Expression of PGC-1α and PGC-1β in PGC1α-KO mice. (a) Level of PGC-1α mRNA in the SN of WT mice, PGC-1α KO mice (PGC1α-KO)
and from PGC1α-KO mice injected with a vector encoding PGC-1α (PGC1α Inj) at 1 month post-injection. Values are expressed in arbitrary units (AU).
WT n = 2; PGC1α-KO n = 5; PGC1α Inj n = 3. (b) Level of PGC-1β mRNA in the SN. Values are expressed in arbitrary units (AU). WT n = 3;
PGC1α-KO n = 3; PGC1α Inj n = 3. Statistical analysis: one-way ANOVA with Newman-Keuls post-hoc test; *p < 0.05.
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chondrial capacity, and could therefore compensate for the
lack of PGC-1α activity [31]. In the SNpc of PGC1α-KO
mice, we measured a modest, non-significant increase in
the level of PGC-1β expression (0.28 ± 0.05 AU), when
compared to WT mice (0.21 ± 0.06 AU; Figure 1b).
Conversely, the abundance of the PGC-1β transcript
was significantly reduced to 0.11 ± 0.02 AU when PGC-1α
was overexpressed three weeks post-injection of the
AAV-PGC-1α vector.
PGC1α-KO nigral dopaminergic neurons accumulate
large-sized mitochondria and display a disorganized
endoplasmic reticulum
Next, we explored by electron microscopy how the loss
of PGC-1α affects mitochondria in nigral dopaminergic
neurons. We analyzed the ultrastructure of organelles in
the soma of neurons located in the SNpc and ventral
tegmental area (VTA) of 10 month-old mice. PGC1α-
KO mice were compared to WT mice, and PGC1α-KO
mice at 4 months after intranigral injection of the AAV-
PGC-1α vector to restore PGC-1α activity in the dopa-
minergic neurons (PGC1α Inj).
In the SNpc, the density of mitochondria in the neur-
onal soma was increased in PGC1α-KO mice (0.91 ±
0.03 mitochondria per μm2), as compared to WT ani-
mals (0.69 ± 0.03 mitochondria per μm2; Figure 2a to c).
We also found that the average mitochondrial size was
significantly larger in dopaminergic neurons of PGC1α-
KO mice (mitochondrial area: 0.140 ± 0.002 μm2), than
in WT mice (0.131 ± 0.002 μm2; Figure 2d). Strikingly,
giant mitochondria (size >1 μm2) were observed in the
neuronal soma of PGC1α-KO mice, while they were ab-
sent in aged WT mice (Figure 2e). The abnormal presence
of giant mitochondria may indicate impaired mitochondrial
dynamics and high levels of oxidative stress in PGC1α-KO
mice. Remarkably, most of these abnormal mitochondrialfeatures were corrected in the SNpc of mice injected with
the AAV-PGC-1α vector. As compared to PGC1α-KO
mice, the density of mitochondria in the neuronal cytosol
was significantly decreased to 0.62 ± 0.02 mitochondria
per μm2 in the PGC1α Inj group, a value similar to WT
mice (Figure 2c). Similarly, the average size of mitochon-
drial section was reduced to 0.121 ± 0.002 μm2 (Figure 2d).
Although some giant mitochondria were still observed
in PGC1α Inj mice, the median size was reduced to
0.089 μm2 in the PGC1α Inj group, versus 0.101 μm2
and 0.102 μm2 in PGC1α-KO and WT, respectively
(Figure 2e). Overall, the expression of PGC-1α in adult
PGC1α-KO mice is associated with the presence of
small-sized mitochondria in the neuronal soma. These
organelles are more sparsely and homogenously dis-
tributed in the cytosol, as indicated by larger minimal
distance between mitochondria, measured using the
nearest neighbor method (Figure 2f ). As compared to
PGC1α-KO (0.61 ± 0.02 μm) and WT (0.63 ± 0.01 μm)
mice, the average minimal distance between mitochondria
was significantly increased to 0.83 ± 0.03 μm following
injection of the AAV-PGC-1α vector. Restored expres-
sion of PGC-1α in adult PGC1α-KO mice prevented
mitochondrial clustering, which is often associated with
mitochondrial dysfunction and cell death [32].
To determine if the loss of PGC-1α activity leads to
overall changes in the number of mitochondria in nigral
dopaminergic neurons, we assessed mitochondrial density
in the axonal projections located inside the striatum. An
AAV8 vector encoding the mitochondria-targeted marker
mitoDsRed was injected in the SNpc of 10 months-old
mice, and the density of mitoDsRed-positive organelles
was quantified in the dorsolateral part of the striatum
(Additional file 1: Figure S1). Mitochondrial accumulation
of mitoDsRed was found in the majority of TH-positive
dopaminergic neurons in the SNpc (Additional file 1:
Figure S1a), and labeled organelles were distributed
Figure 2 (See legend on next page.)
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Figure 2 PGC-1α reduces the number of mitochondria and rescues the abnormal mitochondrial phenotype observed in the SNpc of
PGC1α-KO mice. (a) Electron micrographs of neuronal soma in the SNpc of 10 month-old PGC1α-KO mice, PGC1α-KO mice injected with a
vector encoding PGC-1α (PGC1α Inj) and WT mice. Note the presence of lipofuscin granules (black arrowheads) and giant mitochondria with
disorganized cristae (black arrows). Nu indicates the neuronal nucleus (Nu). (b) Mitochondria are outlined with black lines. Neuronal nuclei
and membranes are outlined with a grey line to indicate the limits of the neuronal cytosol. Note the increase in the density of mitochondrial
clusters in PGC1α-KO mice. Scale bar: 1 μm. (c) Quantification of mitochondrial density reveals a significant increase in PGC1α-KO mice compared to
the other groups. (d) Average area of mitochondria. Note the increased size in PGC1α-KO mice, compared to PGC1α Inj and WT mice. (e) Box and
whisker plots showing the distribution of mitochondrial size in the SNpc of PGC1α-KO, PGC1α Inj and WT mice. The thick line represents the median
and the box indicates the 10th and the 90th percentiles. Whiskers show the extreme values for each group. Note the presence of abnormal, enlarged
mitochondria in PGC1α-KO mice. (f) Nearest neighbor analysis of mitochondrial distribution in the neuronal cytosol, demonstrating reduced clustering
in PGC1α Inj mice. (g) Density of lipofuscin granules, which is significantly increased in the PGC1α Inj group. Statistical analysis: one-way ANOVA with
Newman-Keuls post-hoc test; (C,F,G): WT: n = 79 neurons; PGC1α-KO: n = 89 neurons; PGC1α Inj: n = 113 neurons. (D,E): WT: n = 2729 mitochondria;
PGC1α-KO: n = 3527; PGC1α Inj: n = 2544; **p < 0.01, ***p < 0.001. Micrographs were obtained from 3 animals in each group.
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Figure S1b). Quantification of the density of discrete
labeled punctae in the striatum did not reveal any signifi-
cant difference between PGC1α-KO mice and WTcontrols
(Additional file 1: Figure S1c). As the vast majority of mito-
chondria are expected to reside within the axonal compart-
ment, there is likely no overall change in mitochondria
density in the nigral dopaminergic neurons of PGC1α-KO
mice. Therefore, the increased number of enlarged mito-
chondria present in the soma of these neurons reflects
impaired mitochondrial dynamics caused by the loss of
PGC-1α expression.
Overexpression of PGC-1α also induced the accumula-
tion of lipofuscin granules in nigral neurons (Figure 2g).
The measured density of lipofuscin granules in the
neuronal cytosol of PGC Inj animals was 0.15 ± 0.01
granules/μm2, significantly increased with respect to
PGC1α-KO mice (0.11 ± 0.01 granules/μm2). Lipofuscin
is composed of non-degradable, electron-dense intralyso-
somal material, mainly oxidized proteins and lipids [33],
the accumulation of which is caused in large part by the
deposition of autophagocytosed mitochondria. Lipofuscin
is therefore considered as an indicator of mitophagy
[34,35], and its accumulation might indicate enhanced
mitochondrial turnover in the nigral neurons of mice
injected with the AAV-PGC-1α vector.
In the same animals, we explored if similar changes in
mitochondrial morphology were present in the VTA, a
brain region that contains dopaminergic neurons resist-
ant to PD pathology. Ultrastructural analysis of neuronal
cells inside the VTA did not reveal any overt difference
between WT and PGC1α-KO mice, neither in mitochon-
drial density, nor in the intracellular distribution of
mitochondria (Additional file 2: Figure S2). Notably, giant
mitochondria were not observed in the VTA of PGC1α-
KO mice. Instead, the average surface of mitochondrial
sections in PGC1α-KO mice was even significantly smaller
than in WT (0.133 ± 0.001 vs 0.151 ± 0.001). The con-
trasted effects observed in the SN and VTA underline theselective vulnerability of nigral dopaminergic neurons to
changes in PGC-1α activity.
PGC1α-KO nigral dopaminergic neurons display a
fragmented endoplasmic reticulum, with a reduction in
the number of ER-mitochondria contacts
As functional interactions exist between mitochondria
and ER, we examined ER morphology in the soma of
dopaminergic neurons in the SNpc (Figure 3). WT mice
displayed a normal, parallel-organized ER stack. In stark
contrast, the ER of PGC1α-KO mice appeared disorganized
and fragmented (Figure 3a and b). In PGC1α-KO mice, we
measured in neuronal cells a significant reduction in the
median length of ER segments and a significant decrease in
the number of ER branches compared to WT animals
(Figure 3c and d). By analyzing more closely the size
distribution of ER segments, we found a significant in-
crease in the percentage of small ER segments with a
length ≤0.25 μm, and a corresponding decrease in ER
segments between 0.5 and 1 μm in PGC1α-KO mice
compared to WT mice (Figure 3e). Both of these defects
were significantly rescued by AAV-mediated expression of
PGC-1α (Figure 3e). Next, we examined membrane
contacts between mitochondria and ER (Figure 3f ).
Theses interactions are crucial in a number of physio-
logical processes, including mitochondrial function, mito-
chondrial biogenesis, lipid metabolism, Ca2+ signaling and
cell death [36]. As compared to WT and PGC1α-KO
mice, we observed a significant increase in the propor-
tion of mitochondria making membrane contacts with
the ER in animals injected with the AAV-PGC-1α vector,
further highlighting the role of PGC-1α in controlling
ER/mitochondria interactions.
Overall, nigral neurons of PGC1α-KO mice show pro-
nounced and specific perturbations of mitochondrial
and ER morphology, which reflect profound organelle
dysfunctions. Considering the possible implication of re-
duced PGC-1α activity in aging, we next sought to in-
vestigate whether PGC1α-KO mice display increased
Figure 3 (See legend on next page.)
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Figure 3 Expression of PGC-1α rescues ER morphology in PGC1α-KO mice, and increases the number of mitochondrial contacts with
ER. (a) Electron micrographs of neuronal soma in the SNpc of PGC1α-KO, PGC1α Inj and WT mice. Black arrowheads indicate the presence of
giant mitochondria with disorganized cristae. (b) ER cisternae are colored in light gray. The cell membrane at the border of the neuronal cytosol
is outlined. Note that PGC1α-KO mice display a disorganized and fragmented ER. In WT and PGC1α Inj mice, normal ER stacks are observed. Scale
bar: 1 μm. (c,d) Quantification of the median length of ER profiles and number of branch points per μm of ER. (e) Relative length distribution of
the ER segments in individual neurons from WT, PGC1α-KO and PGC1α Inj mice. Note the overall fragmentation of the ER in neurons from
PGC1α-KO mice. Statistical analysis for c-d: one-way ANOVA with Newman-Keuls post-hoc test; WT: n = 51 neurons; PGC1α-KO: n = 51 neurons;
PGC1α Inj: n = 60 neurons (f) Percentage of mitochondria having membrane contacts with ER. Note that PGC-1α significant increases the proportion
of mitochondria with ER contacts. Statistical analysis: one-way ANOVA with Newman-Keuls post-hoc test; WT: n = 79 neurons; PGC1α-KO: n = 89
neurons; PGC1α Inj: n = 113 neurons; *p < 0.05, **p < 0.001 and ***p < 0.001. Micrographs were obtained from 3 animals in each group.
Ciron et al. Acta Neuropathologica Communications  (2015) 3:16 Page 9 of 20vulnerability to the accumulation of human aSyn, a key
actor in PD pathology.
Reduced PGC-1α activity increases neuronal vulnerability
to α-synuclein toxicity
To assess the resistance of nigral dopaminergic neurons
to pathologic overabundance of aSyn, an AAV2/6 vector
encoding human aSyn (AAV-aSyn) was injected in the
SNpc of young adult PGC1α-KO mice. The vector was
unilaterally injected, to assess the survival of nigral dopa-
minergic neurons with respect to the intact, non-injected
side. AAV-aSyn was injected at a dose of 1 × 107 TU and
compared to the same dose of a control, non-coding vec-
tor. Furthermore, age-matched WT C57BL/6J mice were
similarly injected and used as control with normal
PGC-1α activity. We assessed the number of surviving
nigral neurons positive for the dopaminergic marker
tyrosine hydroxylase (TH), at 3 and 6 months post-
vector injection. At 3 months, there was no loss of
dopaminergic neurons, both in WT and PGC1α-KO
mice overexpressing human aSyn (Figure 4a). Never-
theless, immunohistochemistry revealed a clear overex-
pression of human aSyn in nigral TH-positive neurons
(Figure 4b).
Remarkably, at 6 months post-injection we measured a
20.5 ± 3.3% loss of TH-positive neurons in the SNpc of
PGC1α-KO mice injected with AAV-aSyn, which is
significantly different as compared to PGC1α-KO mice
injected with the non-coding vector (Figure 4c to e).
The loss of neurons was also significantly increased as
compared to WT mice injected with AAV-aSyn, in
which the SN remained intact (Figure 4c to f ). When
we compared male and female PGC1α-KO mice injected
with AAV-aSyn, we found that the loss of TH-positive
neurons was gender-dependent (29.9 ± 3.6% in males ver-
sus 11 ± 3.2% in females) (Figure 4d). The loss of dopa-
minergic neurons was similarly increased in PGC1α-KO
mice (29.1 ± 4.1%) compared to WT mice (10.4 ± 6.3%)
when measuring the number of neurons positive for the
dopamine transporter (DAT) (Student’s t test, p = 0.03).
Immunohistochemistry for indicators of apoptotic cell
death revealed a positive signal for cleaved caspase-3
only in the SNpc of PGC1α-KO mice injected with theaSyn-expressing vector, on the side ipsilateral to the in-
jection (Additional file 3: Figure S3). To assess the loss
of nigrostriatal dopaminergic axons, TH immunoreactiv-
ity was further quantified in the striatum. Overall, the
loss of striatal TH was below 15% and did not reveal any
significant difference between groups (Additional file 4:
Figure S4). Indeed, as late as 6 months post-injection,
compensatory rescue of striatal dopaminergic innerv-
ation could mask the initial partial loss of fibers caused
by aSyn overexpression [37].
Expression of α-synuclein in PGC1α-KO neurons induces
the production of reactive oxygen species, which is
suppressed by PGC-1α
PGC1α null mice were previously shown to display a
higher sensitivity to oxidative stress, caused by the re-
duced expression of factors involved in the detoxification
of ROS [18]. Hence, to explore possible causes for aSyn
toxicity in conditions of low PGC-1α activity, we assessed
the production of ROS in the medium of primary neur-
onal cultures derived from the cortex of either PGC1α-
KO mice or WT mice. When 7 day-old neuronal cultures
were co-infected with AAV-aSyn in combination with a
non-coding control vector, we measured a clear increase
in the amount of hydrogen peroxide (H2O2) produced
in the culture medium at 7 days post-infection, as
compared to non-infected cultures (Figure 5). Remark-
ably, co-transduction of neurons with the AAV-PGC-1α
vector significantly reduced the production of H2O2
caused by aSyn expression (Figure 5a). In cortical neurons
derived from WT mice, neither the expression of aSyn,
nor the co-expression of aSyn and PGC-1α induced any
significant change in the production of H2O2 as compared
to non-infected neuronal cultures (Figure 5b). The pro-
duction of ROS in PGC1α-KO neurons expressing aSyn
further highlights the specific neuronal vulnerability to
aSyn-induced toxicity in conditions of low PGC-1α activity.
PGC-1α null neurons expressing human α-synuclein have
reduced basal oxygen consumption
Next, we used primary cortical neurons derived from
PGC1α-KO mice to explore the effect of aSyn on mito-
chondrial function. Neurons were transduced with AAV
Figure 4 (See legend on next page.)
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Figure 4 Expression of human aSyn induces the loss of neurons positive for dopaminergic markers in the SNpc of PGC1α-KO mice.
PGC1α-KO mice or WT mice were injected in the SNpc with an AAV2/6 vector encoding aSyn or a non-coding vector (NCV). (a) At 3 months
post-injection, there is no significant loss of TH-positive neurons in the SNpc (WT: n = 5 and PGC1α-KO: n = 10). (b) Overexpression of human aSyn
is detectable by immunohistochemistry in nigral TH-positive neurons. Scale bar: 100 μm. (c) At 6 months post-injection, a significant loss of TH-positive
neurons is observed in the SNpc of PGC1α-KO mice injected with AAV-aSyn. Statistical analysis: two-way ANOVA with Newman-Keuls post-hoc test;
PGC1α-KO + aSyn: n = 18; PGC1α-KO +NCV: n = 5; WT + aSyn: n = 14; WT + NCV: n = 8; **p < 0.01, ***p < 0.001. (d) Analysis according to gender
reveals that male PGC1α-KO mice are significantly more prone to aSyn-induced loss of TH neurons than female mice. Student’s t test: n = 9
for each gender; **p < 0.01. (e,f) Representative photomicrographs showing the loss of TH neurons in the AAV-aSyn injected hemisphere of
PGC1α-KO mice (e), as compared to no loss in WT mice (f). The non-injected side (NInj) is shown for comparison. Scale bar: 100 μm.
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measured extracellular oxygen flux to evaluate mito-
chondrial activity. Oxygen consumption rate (OCR) was
assessed in basal conditions, in presence of carbonyl
cyanide m-chlorophenyl hydrazone (CCCP), a compound
dissipating the proton gradient across the mitochondrial
membrane, and in presence of oligomycin, an inhibitor of
the mitochondrial ATP synthase (Figure 6a). We observed
that overexpression of aSyn induces a significant decrease
in basal OCR in PGC1α-KO neurons (Figure 6b). This ef-
fect of aSyn was completely suppressed by the expression
of PGC-1α. The changes in OCR appeared very similar
in presence of oligomycin, indicating that the reduced
respiration found in PGC1α-KO neurons expressing
aSyn is not caused by any defect in ATP synthase activity.
Therefore, aSyn is likely to lower the overall ETC activity,
which can be corrected by restoring PGC-1α expression
(Figure 6c).
However, when the maximal respiration rate was mea-
sured following addition of the uncoupling agent CCCP
(Figure 6a), we found that the spare respiratory capacity
was significantly reduced in neurons overexpressing both
aSyn and PGC-1α (Figure 6d). Furthermore, the coup-
ling efficiency of the cells, which is indicated by the
percentage of basal mitochondrial respiratory rate used
for ATP synthase activity, was significantly reduced by
PGC-1α expression (Figure 6e). Overall, these results
indicate that aSyn perturbs mitochondrial function in
PGC1α-KO cells, mainly leading to an impairment of
basal respiration which is consistent with the produc-
tion of ROS observed in these neurons. Expression of
PGC-1α rescues this effect, although the respiratory
capacity of the neurons remains significantly lower
than in neurons that are not expressing aSyn.
PGC-1α expression protects male PGC1α-KO mice against
aSyn toxicity in the SNpc
The significant protective effect observed with the
AAV-PGC-1α vector prompted further investigation
to determine if the same vector could prevent neuronal
degeneration in vivo. To address this question, we assessed
if injection of the AAV-PGC-1α vector in the SNpc of
PGC1α-KO mice could protect nigral neurons against
aSyn toxicity. As intranigral injection of the AAV-aSynvector produced only mild neurodegenerative effects in
our previous experiment, we used another vector design
including an optimized kozak sequence and the WPRE en-
hancer element to increase the rate of aSyn translation. In
a previous study, this vector was found to express higher
levels of aSyn in the rat SNpc [26]. We first assessed if the
co-expression of aSyn and PGC-1α could be achieved on
the long-term following co-injection of the two vector sus-
pensions. Indeed, we could detect by immunohistochemis-
try a clear overexpression of both mouse PGC-1α and
human aSyn in a significant proportion of TH-labeled
dopaminergic neurons, 6 months post-injection of the vec-
tor mix (Figure 7).
A gender-balanced cohort of young adult PGC1α-KO
mice was co-injected in the SNpc with the optimized
AAV2/6 vector encoding aSyn (1 × 107 TU), together with
a control non-coding vector (5 × 106 TU). Six months
post-injection, PGC1α-KO mice indeed showed a signifi-
cant, 29.1 ± 4.3% loss of nigral TH-positive neurons in the
ipsilateral SNpc (Figure 8a to c). In male mice, nigral de-
generation induced by the optimized vector reached 34 ±
8.4% loss of TH-positive neurons, as compared to the
non-injected side (Figure 8b). In female mice, the extent
of dopaminergic neuron loss was slightly lower (25.8 ±
4.8%). With the optimized aSyn-expressing vector,
neuronal loss in female mice was approximately twice
higher than in our previous experiment (see Figure 4d),
no more significantly different from their male counter-
parts. In the striatum, the effect on dopaminergic axons
was also more pronounced. We measured an average loss
of TH immunoreactivity of 22.7 ± 3.4% over the whole
striatum, reaching 26.4 ± 7.4% in male, and 20.2 ± 3.1% in
female mice (Figure 8e). To verify if the loss of the dopa-
minergic marker TH was indeed associated with neuronal
degeneration, we performed stereological estimates of the
number of Nissl-stained neuronal nuclei in the SNpc. We
found an overall 18.7 ± 3.0% reduction in the number of
neuronal nuclei in the injected SNpc (18.0 ± 6.0% in male
and 17.1 ± 3.6% in female mice), consistent with aSyn-
induced neuronal loss (Figure 8f).
Next, we assessed the effect of PGC-1α expression on
nigral neurons. The co-injection of the AAV-PGC-1α
vector (5 × 106 TU) showed protective effects against
degeneration induced by the expression of human aSyn
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Figure 5 PGC-1α protects primary neuronal cultures of PGC1α-KO mice against oxidative stress induced by aSyn. Seven day-old primary
neuronal cultures were derived from the cerebral cortex of PGC1α-KO (a) or WT mice (b). Individual cultures were co-infected either with the
non-coding and aSyn vectors (NCV + aSyn), or with the PGC-1α and aSyn vectors (PGC1α + aSyn). H2O2 concentrations were measured in cell
culture media at 7 days post-infection. Note the significant increase in H2O2 production in PGC1α-KO neurons expressing aSyn, which is prevented
by PGC-1α expression. In contrast, aSyn does not cause any significant increase in H2O2 production in neurons derived from WT mice. Statistical
analysis: one-way ANOVA with Newman-Keuls post-hoc test; NI: n = 14; NCV + aSyn: n = 12; PGC1α + aSyn: n = 14; ***p < 0.001. Note that raw
values of H2O2 production were obtained from separate experiments for neurons derived from PGC1α-KO and WT mice and are therefore
not comparable.
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compared to the 29.1 ± 4.3% loss of TH-positive neurons
in PGC1α-KO mice injected with AAV-aSyn, we found a
significantly reduced neuronal loss (6.4 ± 9.8%, p < 0.05)
following co-injection with AAV-PGC-1α (Figure 8a).
When we compared the effect of PGC-1α between gen-
ders, PGC-1α expression completely rescued TH-positive
nigral neurons from aSyn toxicity in males, but did not
show any effect in female mice (Figure 8b). Analysis of
striatal TH immunoreactivity confirmed the neuroprotec-
tion observed in male mice only (Figure 8e). Finally, there
was a trend towards higher number of Nissl-positive nuclei
in the SNpc of male mice injected with AAV-PGC-1α, sug-
gesting that expression of PGC-1α was able to rescue neu-
rons from aSyn toxicity (Figure 8f).
As we previously found a major effect of PGC-1α on
the production of ROS, we analyzed the accumulation of
4-hydroxynonenal (HNE), a histological marker for lipid
peroxidation, in the SNpc of these animals. HNE deposition
was detected in the SNpc of male PGC1α-KO mice, on the
side expressing human aSyn (Figure 9a). In contrast, when
AAV-PGC-1α was co-injected with the aSyn-expressing vec-
tor, the HNE signal was completely suppressed, further dem-
onstrating the protective effect of restoring PGC-1α activity
on cellular damage caused by ROS production (Figure 9b).
Altogether, these results underline the neuroprotective
effect of PGC-1α against the toxic effect of aSyn accu-
mulation. Particularly in male mice, the loss of PGC-1α
activity prompts neuronal loss when aSyn is chronically
expressed in the SNpc, highlighting the role of thistranscriptional co-activator in gender-dependent neur-
onal resistance to degeneration.
Discussion
Age-related neurodegenerative diseases are often character-
ized by downregulated PGC-1α activity and perturbed ex-
pression of PGC-1α transcriptional targets [38-40,21,41].
This transcriptional co-regulator has therefore emerged as
a potential therapeutic target to oppose neuronal de-
generation in PD. Here, we show that nigral dopamin-
ergic neurons of PGC-1α null mice, which presumably
mirror some aspects of premature brain aging, display
profound ultrastructural alterations of ER and mito-
chondria. Furthermore, reduced PGC-1α activity leads
to increased vulnerability to aSyn, specifically in male mice.
This effect is associated with increased oxidative damage,
consistent with the role of PGC-1α in mitochondrial func-
tion and ROS detoxification. In this context, expression of
full-length PGC-1α using an AAV vector can rescue aSyn-
induced neurodegeneration in male mice.
To determine how reduced PGC-1α activity affects ni-
gral neurons, we analyzed changes in mitochondrial
morphology and density. Despite the transcriptional role
of PGC-1α in mitochondrial biogenesis, we do not find
any major decrease in the density of mitochondria, neither
in the striatal dopaminergic axons, nor in the neuronal
soma located in the SN. Therefore, dopaminergic neurons
are likely to compensate for the loss of full-length
PGC-1α, possibly via other PGC-1 variants. A mutant
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Figure 6 (See legend on next page.)
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Figure 6 Alpha-synuclein impairs basal mitochondrial respiration in PGC1α-KO neurons. Primary neuronal cultures were derived from the
cerebral cortex of PGC1α-KO mice and co-transduced with either a non-coding AAV vector (NCV), an AAV vector encoding human aSyn, or with
an AAV vector encoding PGC-1α (PGC1α). (a,b) Basal oxygen consumption was measured from individual cultures in the conditions NCV alone
(n = 15), NCV + aSyn (n = 20), NCV + PGC1α (n = 19) and aSyn + PGC1α (n = 15). (a,d) Some of the individual cultures were treated with CCCP,
in order to determine the percentage of spare respiratory capacity (d): NCV alone (n = 6), NCV + aSyn (n = 10), NCV + PGC1α (n = 4) and aSyn + PGC1α
(n = 5). Other individual cultures were treated with oligomycin to determine (c) the oligomycin-resistant residual respiration and (e) the percentage of
oxygen consumption used for ATP production: NCV alone (n = 9), NCV + aSyn (n = 10), NCV + PGC1α (n = 10) and aSyn + PGC1α (n = 10).
Statistical analysis: two-way ANOVA with Newman-Keuls post-hoc test. (b-d): significant interaction between the aSyn and PGC1α effects,
*p < 0.05; **p < 0.01; ***p < 0.001; (e): significant group effect of PGC1α, ***p < 0.001.
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in the absence of full-length PGC-1α [29]. However,
this factor has been shown to regulate a gene program
that is clearly distinct from full-length PGC-1α [42].
Instead, PGC-1β could support mitochondrial biogenesis
[31]. Although PGC-1β is non-significantly increased in
the SN of PGC1α-KO mice, its expression is reduced when
PGC-1α is overexpressed, demonstrating a relationship in
the activity of these two transcriptional co-factors
(Figure 1b). PGC-1β is involved in basal mitochondrial
biogenesis, whereas the role of PGC-1α is rather to
adapt cell metabolic activity, for instance by inducing
mitochondrial proliferation in mitochondrial disease
[43,44]. Remarkably, myocytes lacking both PGC-1α
and β show no difference in mitochondrial content,
despite a clear reduction in ETC activity, suggesting
that these two parameters are not necessarily coupled,
and that PGC-1 activity is primarily involved in adapt-
ing oxidative capacity [45].
PGC1α-KO mice display clear alterations in mitochon-
drial morphology. In particular, giant mitochondria are
observed in nigral neurons of 10 month-old PGC1α-KO
mice, while they are nearly absent from WT mice. In the
absence of PGC-1α, PGC-1β might promote mitochon-
drial fusion and elongate mitochondrial tubules [46].
Alternatively, the accumulation of giant mitochondria
could be due to a selective reduction in mitochondrial
fission. Abnormally large mitochondria are indicative
of organelle senescence, often accompanied by struc-
tural alterations such as swelling, partial loss cristae,Figure 7 Co-injection of AAV-aSyn and AAV-PGC-1α vectors induces ex
shows the co-expression of PGC-1α and aSyn in TH-positive neurons in the SNand almost complete destruction of ETC components
[47]. These structural changes underlie functional defi-
ciencies such as disturbed energy metabolism, and sub-
sequent decrease in ATP production, often associated
with age-dependent mitochondrial DNA mutations [48].
The accumulation of giant mitochondria in nigral dopa-
minergic neurons of PGC1α-KO mice may therefore be a
sign of premature neuronal aging.
Conversely, injection of the AAV-PGC-1α vector in the
SNpc produces clear changes in mitochondrial dynamics.
The size and clustering of mitochondria are both reduced,
consistent with increased mitochondrial fission. PGC-1α
controls the expression of the GTPases dynamin-related
protein 1 (Drp1) and mitofusin 2 (Mfn2) in human skel-
etal muscle and mouse ventral midbrain neurons [19,49].
These factors have critical roles in mitochondrial fission
(Drp1) and fusion (Mfn2), regulating tubular mito-
chondrial networks. Defects in fission or fusion may
cause neuronal death by limiting mitochondrial motility,
decreasing energy production, impairing Ca2+ buffering,
and promoting oxidative stress and mtDNA deletion [50].
Overall, the expression of PGC-1α in adult nigral neurons
can suppress the signs of premature mitochondrial senes-
cence that are found in PGC1α-KO mice.
Tightly related to the aging process, mitochondrial
turnover is essential to replace damaged mitochondria
with functional, replicating organelles. Several indicators
suggest that the rate of mitochondrial turnover is af-
fected by PGC-1α in nigral dopaminergic neurons. A
significant increase in the number of mitochondria,pression of PGC-1α and aSyn in nigral neurons. Immunostaining
pc of PGC1α-KO mice, at 6 months post-AAV injection. Scale bar: 20 μm.
Figure 8 (See legend on next page.)
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Figure 8 PGC-1α expression protects against aSyn toxicity in the SNpc of male PGC1α-KO mice. PGC1α-KO mice were co-injected with
two AAV2/6 vectors encoding for aSyn and PGC-1α (PGC1α + aSyn). The control group is injected with a non-coding vector instead of AAV-PGC-1α
(NCV + aSyn). (a) Loss of TH-positive neurons in the SNpc at 6 months post-injection. PGC-1α overexpression induces significant protection against
aSyn toxicity. Statistical analysis: Student’s t test; PGC1α + aSyn: n = 10; NCV + aSyn: n = 10; *p < 0.05. (b) Analysis according to gender shows that the
protective effect of AAV-PGC-1α is specific to male mice. Statistical analysis: two-way ANOVA with Newman-Keuls post-hoc test; PGC1α + aSyn: n = 4
males and 6 females; NCV + aSyn: n = 5 males and 5 females; *p < 0.05. (c,d) Representative photomicrographs showing the loss of TH-positive neurons
in the SNpc of NCV + aSyn mice (c), as compared to PGC1α + aSyn mice (d). The non-injected side (NInj) is shown for comparison. Scale bar: 500 μm.
(e) Gender-specific analysis reveals significant protection of striatal TH fibers only in male mice PGC1α-KO mice injected with the AAV-PGC-1α vector.
Statistical analysis as in (b); *p < 0.05 and #p = 0.058. (f) Stereological gender-specific analysis of the loss of Nissl-positive neurons in the SNpc. Statistical
analysis as in (b): # p = 0.070, § p = 0.059.
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product of autophagic degradation, indicate a low rate of
mitochondrial turnover in PGC1α-KO mice. Indeed, au-
tophagic elimination of giant mitochondria could be fur-
ther compromised by the large size of these organelles
[51]. Conversely, neuronal soma over-expressing PGC-
1α display small-sized mitochondria, together with en-
hanced accumulation of lipofuscin granules, consistent
with high mitochondrial turnover.
The ER is an organelle closely associated to mitochon-
dria, which may have important function in mitochondrial
dynamics including fission events [52]. The interface
between ER and mitochondria is called the mitochondria-
associated ER membrane (MAM), which has critical roles
in Ca2+ signaling and lipid exchange between organelles.
In PGC1α-KO mice, we observe disrupted ER morph-
ology, with abundant free ribosomes and scattered, frag-
mented cisternae, which have lost their parallel stackFigure 9 PGC-1α prevents oxidative stress induced by aSyn in vivo. (a
6 months after co-injection of PGC1α-KO mice with an AAV2/6 vector enco
of the HNE staining in the SNpc of PGC1α-KO mice expressing aSyn. (b) Co
PGC-1α overexpression suppresses signs of oxidative stress in PGC1α-KO mic
Scale bar: 100 μm.arrangement. PGC-1α increases the number of membrane
contacts between the ER and the mitochondria (Figure 3f).
Notably, aSyn has been recently localized in the MAM,
with pathogenic mutations affecting mitochondrial
dynamics [53].
Here, we find that the loss of PGC-1α enhances the
vulnerability of dopaminergic neurons to aSyn toxicity in
the SNpc. Alpha-synuclein has been shown to interfere
with a number of cellular processes including membrane
trafficking [54], autophagy [55], proteasomal degradation
[56] and mitochondrial function [57]. Alpha-synuclein
can directly affect mitochondrial morphology, by inter-
acting with mitochondrial membranes containing cardio-
lipin and promoting mitochondrial fragmentation [12,11].
Moreover, aSyn can contribute to neurodegeneration by
inducing ER stress [58,59], which may further precipitate
mitochondrial perturbations. A few reports have charac-
terized the mitochondrial dysfunction caused by the) Immunostaining for HNE, a marker for oxidative damage, at
ding aSyn and a control non-coding vector (NCV). Note the presence
-injection with AAV2/6 vectors encoding aSyn and PGC-1α. Note that
e expressing aSyn. The non-injected side (NInj) is shown for comparison.
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interact with complex I, interfere with its function and
lead to increased ROS production [60,61]. Alpha- and
beta-synucleins were recently reported to reduce basal
respiration in primary neurons [62]. We find that aSyn ex-
pression in PGC-1α null neurons leads to a significant de-
crease in mitochondrial respiration, consistent with the
reported effects of aSyn on ETC. activity. Remarkably, the
aSyn-induced decrease in mitochondrial respiration can
be rescued by de novo expression of PGC-1α. However,
PGC-1α expression also decreased the reserve respiratory
capacity of the neuronal cells, similar to previous results
obtained in neurons derived from the ventral midbrain
[19]. It will be important to explore the consequences of
PGC-1α on long-term neuronal viability, as the capacity
of the cells to adapt their mitochondrial respiration could
be important to meet with high ATP demand. Neverthe-
less, these results suggest that reduced PGC-1α activity
can contribute to the mitochondrial dysfunction caused
by aSyn. It is also possible that other mechanisms, inde-
pendent from the mitochondrial function, are the cause of
the increased vulnerability of PGC-1α-null neurons accu-
mulating aSyn, as suggested by a recent study which
found signs of enhanced aSyn oligomerization [22].
Chronic overexpression of PGC-1α has previously
been reported to decrease the expression of dopamin-
ergic markers in the adult SN, consistent with downreg-
ulation of the transcription factor Pitx3 [19,23]. We
found no such evidence in PGC1α-KO mice. This is sur-
prising as the injection of the AAV-PGC-1α vector leads
to a 10-fold higher level of PGC-1α mRNA compared to
WT mice (Figure 1a). It is plausible that local PGC-1α
overexpression does not produce the same effects in
the normal SN and in the context of a PGC-1α-null
brain, where other cells still fail to express this protein.
Remarkably, and in contrast to previous experiments
using WT neurons, we did not find any significant in-
crease in basal respiration in PGC1α-KO neurons overex-
pressing PGC-1α (Figure 6b), suggesting that these neurons
may also have developed compensatory mechanisms to
regulate mitochondrial function in the absence of PGC-1α.
Altogether, these results suggest that in conditions where
PGC-1α is downregulated, nigral dopaminergic neurons
may better tolerate therapeutic strategies that enhance
PGC-1α activity, even in a chronic manner.
Enhanced vulnerability to aSyn, as well as the rescue
effect of overexpressing PGC-1α, was predominantly ob-
served in male PGC1α-KO mice. PGC-1α has also been
identified as a male-specific disease modifier of human
and experimental amyotrophic lateral sclerosis [63]. This
gender effect is reminiscent of the higher incidence of
PD in men than in women [64]. Studies on gene expres-
sion in nigral dopaminergic neurons from healthy con-
trol and PD subjects have shown differences betweenmales and females [65], which suggests that transcrip-
tional activity of specific set of genes could be an im-
portant factor in the male vulnerability to disease.
Remarkably, a set of genes associated to mitochondrial
function appears to be deregulated mainly in male PD
cases. It will be critical to determine if PGC-1α activity
is involved in this difference. Another possible explan-
ation for the sexual dimorphism observed in PGC1α-KO
mice may lie in the response to sex hormones. Indeed,
expression of the estrogen receptor α (ERα) is linked to
PGC-1α activity [66]. Although the neuroprotective ef-
fects of estrogens is still debated in PD [67], it is pos-
sible that expression of estrogen receptors is reduced
in PGC1α-KO mice, increasing the vulnerability of
male mice to pathogenic factors. Mitochondrial activity
may also have a critical role in gender asymmetry. As the
mitochondrial genome is transmitted through the maternal
lineage, deleterious mitochondrial DNA (mtDNA) muta-
tions that affect only males will not be subject to natural
selection, possibly contributing to the sexual dimorphism
observed in aging or neurodegeneration [68].
There is increasing evidence for the critical role of
PGC-1α in PD, prompting further investigation on the
therapeutic potential of modulating its activity. Pioglita-
zone, an agonist of peroxisome proliferator-activated
receptor-γ (PPARγ) promoting PGC-1α activity, is notably
neuroprotective in the MPTP model of PD [69-71]. A
phase II clinical trial is currently conducted to assess the
effect of pioglitazone in early PD.
Conclusions
Using a genetic aSynbased approach, the present study
further highlights the protective role of PGC-1α in nigral
dopaminergic neurons. Preserving PGC-1α activity in the
SNpc may prevent age-related alterations underlying
neuronal vulnerability in PD. In addition, our results indi-
cate a role for PGC-1α in the effect of sex and age on the
risk of developing PD. Further elucidating the neuropro-
tective role of PGC-1α might lead to the development of
novel therapeutic strategies.
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Additional file 1: figure S1. PGC1α-KO mice have normal density of
mitochondria in the striatal dopaminergic axons. (a) MitoDsRed
fluorescence colocalizing with TH-positive neurons in the substantia nigra
of a 10 months-old mouse injected with the AAV-mitoDsRed vector. Scale
bar: 200 μm. (b) MitoDsRed fluorescence colocalizing with TH-positive
axonal fibers in the dorsolateral striatum of a mouse injected with the
AAV-mitoDsRed vector. Scale bar: 100 μm. (c) Relative quantification of
the number of mitoDsRed-positive discrete particles normalized to the
Ciron et al. Acta Neuropathologica Communications  (2015) 3:16 Page 18 of 20area of TH immunoreactivity in randomly selected regions of the dorsolateral
striatum. Data points are indicated on the bar graph for each mouse from
the WT (n = 4) and PGC1α-KO (n = 5) cohorts. Open squares represent
male mice and open circles represent female mice in each group. Statistical
analysis: two-tailed Student’s t test with equal variance; ns: non-significant
(p = 0.32).
Additional file 2: figure S2. Loss of PGC1-1α does not cause any major
abnormal mitochondrial phenotype in neuronal cells localized in the VTA.
(a) In neuronal cells of the VTA, PGC1α-KO and WT mice display similar
mitochondrial density. (b) Average surface of mitochondrial area in PGC1α-KO
and WT mice. (c) Nearest neighbor analysis of the minimal distance between
mitochondria showing a similar distribution of the organelles in both groups.
(d) Accumulation of lipofuscin granules in the VTA of PGC1α-KO and WT mice.
Statistical analysis: Student’s t test with equal variance; (b) WT n = 4110
mitochondria; PGC1α-KO n = 7265 mitochondria; (A,C,D): WT n = 51
neurons; PGC1α-KO n = 95 neurons; ***p < 0.001. Micrographs were
obtained from 3 animals in each group.
Additional file 3: figure S3. Overexpression of aSyn leads to detectable
cleaved Caspase 3 signal in PGC1α-KO mice. (a) Positive signal for cleaved
Caspase 3 signal is detected in the hemisphere injected with AAV-aSyn in
the SNpc of PGC1α-KO mice. (b) No positive immunostaining for cleaved
Caspase 3 can be detected in WT mice at 6 months post-injection. The
non-injected side is shown for comparison. Scale bar: 100 μm.
Additional file 4: figure S4. Loss of dopaminergic axons in the
striatum of PGC1α-KO and WT mice overexpressing aSyn. PGC1α-KO mice
or WT mice were injected in the SNpc with an AAV2/6 vector encoding
aSyn or a non-coding vector (NCV). (a) No significant difference between
groups is found in the striatal density of TH-positive fibers. Statistical ana-
lysis: two-way ANOVA with Newman-Keuls post-hoc test; PGC1α-KO + aSyn:
n = 18; PGC1α-KO +NCV: n = 5; WT + aSyn: n = 14; WT +NCV: n = 8. (b) Al-
though the loss of striatal TH density tends to be higher in male
PGC1α-KO mice overexpressing aSyn, there is no significant difference be-
tween genders. Statistical analysis: Student’s t test with equal variance; n =
9 for male and female mice.
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